Led by David Page of the Whitehead Institute and the Massachusetts Institute of Technology, this collaboration explores contributions of the female-specific inactive X chromosome (Xi) and the male-specific Y chromosomes to the ASD sex bias. Page’s lab has previously shown that Xi modulates gene expression across the genome,9 which might underlie the female protective effect if it mitigates effects of deleterious variants.10 Given this possibility, the Page lab has been characterizing the Xi and its epigenomic features, including the extent of X inactivation. While genes on Xi can escape inactivation, the Page lab showed that their transcript levels were less than that observed on the active X chromosome. For example, in cell cultures in vitro, they found that genes expressed from Xi are in fact partially repressed, as measured by the degree of their histone modifications (both active and repressive marks) and transcription levels. Xi promoters were also depleted for active histone marks, and the amount of these mark relative to repressive marks correlated with transcription levels. This effect was also observed for ASD-associated genes on the Xi.
Gesmira Molla, a graduate student in the Page lab, presented her work parsing genetic and hormonal influences on sex differences in marmosets. Marmosets lend themselves to this question because of their sibling chimerism: Marmosets are usually born as twins, and can carry cells with their sibling’s genetic makeup due to fusing of placentas during prenatal development. Their microglial cells in the brain are chimeric, which means a male marmoset can carry XX microglia derived from his sister, and vice versa. This setup can help disentangle genetic and hormonal contributors to sex differences. Molla reported that measures of gene expression and chromatin accessibility across the genome followed patterns specific to the XX or XY status of an individual cell, regardless of the anatomical sex of the marmoset, including ASD-associated KDM6A. In contrast, other genes (e.g., CAJA-E or TGFB2) showed expression that reflected the anatomical sex of the animal.
Chris Glass of the University of California, San Diego focused on the function of MEF2C in microglia, which are particularly sensitive to their environment. MEF2C encodes a transcription factor, and MEF2C haploinsufficiency causes a syndromic form of ASD. MEF2C binding sites are enriched in active enhancer regions of the genome in microglia across multiple species, including humans. In human iPSC-derived microglia in vitro, cells lacking a copy of MEF2C take on a pro-inflammatory phenotype, reduce their phagocytosis and migration, and develop lysosomal dysfunction.11 When microglia lacking both copies of MEF2C are engrafted into the brains of newly born mice to see how they will fare in an in vivo environment, native neurons take on ASD-related features such as altered neuronal density and improper synaptic connections in the hippocampus. Finally, MEF2C-dependent enhancers were enriched for motifs that suggest MEF2C works to drive TGF-β signaling.
Celina Nguyen, a graduate student in Nicole Coufal’s lab at the University of California, San Diego, addressed potential mechanisms behind Y chromosome–induced changes in microglia function. The Nicole Coufal lab has previously found that as Y chromosome dosage increases, microglia decrease phagocytosis and show lysosome dysfunction. To begin to understand the mechanisms behind this, Nguyen identified enhancers across the genome that were sensitive to Y chromosome dosage in microglia. For example, increasing Y content increased transcripts for an ASD gene called ADRB2, which was also associated with increased marks of chromatin accessibility and histone marks of active enhancers. The enhancers contained sequence motifs for several transcription factors, including those on autosomes (e.g., RFX) and on sex chromosomes (ZFY and ZFX). ZFX and ZFY binding sites overlapped with a majority of these Y-sensitive enhancers, and were enriched for ASD-associated genes.